Eli Lilly and Company’s Stock Price Soars to $781.10, Marks Impressive 5.95% Growth

Eli Lilly and Company (LLY)

781.10 USD +43.90 (+5.95%) Volume: 7.38M

Eli Lilly and Company’s stock price has surged to 781.10 USD, experiencing a significant trading session increase of +5.95% and a remarkable YTD growth of +34.00%. The robust trading volume stands at 7.38M, reflecting the strong investor confidence in LLY’s market performance.

Latest developments on Eli Lilly and Company

Eli Lilly & Co’s stock price is on the rise, driven by booming sales of weight-loss drugs Zepbound and Mounjaro. The pharmaceutical giant has raised its 2024 sales forecast by $2 billion, and its Q1 2024 earnings have surpassed estimates. Despite supply issues, the company’s Q1 profit was better than expected, thanks to strong sales of Zepbound and Mounjaro. The demand for these weight-loss drugs continues to fuel growth, prompting Eli Lilly to assure investors of its ability to manage the high demand.

A look at Eli Lilly and Company Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Eli Lilly & Company seems to have a positive long-term outlook. The company scores high in momentum, indicating strong market performance and investor interest. Additionally, Eli Lilly & scores well in growth, suggesting potential for future expansion and development. While the company’s value and dividend scores are moderate, its resilience score is also average. Overall, Eli Lilly & Company appears to be in a favorable position for continued success in the pharmaceutical industry.

Eli Lilly & Company is a global pharmaceutical company that focuses on discovering, developing, and selling a wide range of products for both humans and animals. With a diverse product portfolio that includes neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products, Eli Lilly & serves customers in countries worldwide. The company’s strong momentum score reflects its solid market performance, while its growth score indicates potential for future growth and innovation. Despite average scores in value, dividend, and resilience, Eli Lilly & Company appears well-positioned for continued success in the pharmaceutical market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma